Prostate carcinoma

This study tests a procedure called TULSA that uses MRI images to guide high-energy ultrasound waves to destroy prostate cancer tumors. About 21 adults with early-stage prostate cancer that shows up on MRI will receive this heat-based treatment. The goal is to see if the approach…

This study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can lowe…

This study tests whether a one-time procedure called brachytherapy, where tiny radioactive seeds are placed directly into the prostate, can control intermediate risk prostate cancer without needing additional treatments. Three hundred men with specific tumor features (Gleason sco…

This study tests whether adding capivasertib to standard hormone therapy (abiraterone plus prednisone and ADT) can slow cancer growth better than standard therapy alone. It includes about 1,000 men with newly diagnosed, hormone-sensitive prostate cancer that has spread and has a …

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This phase II trial tests whether green tea catechins (GTC) can prevent low-risk prostate cancer from progressing in men on active surveillance. 360 participants will receive either GTC or a placebo daily. The study measures changes in a tumor growth marker (Ki-67) in biopsy samp…

This phase II study tests whether giving an extra-high radiation dose directly to the main prostate tumor, while treating the rest of the prostate with standard SBRT, can reduce the chance of cancer coming back. About 91 men with intermediate-risk prostate cancer will receive fiv…

This study is for men whose prostate cancer has returned after prostate removal surgery, shown by a rising PSA. It compares standard radiation therapy alone versus radiation plus a drug called apalutamide, which blocks male hormones that fuel cancer growth. The goal is to see if …

This early study tests the safety of TheraSphere PCa, tiny radioactive glass beads injected into the prostate to treat localized prostate cancer. The trial involves 36 men with favorable intermediate-risk cancer and aims to find the maximum safe radiation dose. Researchers will m…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This phase III trial tests whether adding the drug apalutamide to standard hormone therapy and radiation helps men with prostate cancer that has spread to nearby lymph nodes after surgery. About 586 participants will receive either the usual treatment or the usual treatment plus …

This phase 3 trial tests whether treatment for high-risk prostate cancer can be personalized based on a patient's genetic risk score. For those with a low genetic risk, a shorter course of hormone therapy plus radiation may be as effective as the standard 24-month treatment, with…

This phase 2 study tests a combination of hormone therapy, chemotherapy, and an immunotherapy drug (nivolumab) in men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively. The tr…

This study tests whether adding abiraterone and prednisone to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has come back after surgery or radiation. About 310 men will receive either hormone therapy or hormone therapy plus abirate…

This phase 2 trial tests whether giving hormone therapy before prostate surgery helps men with high-risk prostate cancer recover erectile function better. About 90 men will receive either apalutamide alone or a combination of apalutamide, abiraterone, GnRH agonist, and prednisone…

This phase 2 trial tests whether white button mushroom extract can lower PSA levels in men with prostate cancer that has returned after treatment or is low-risk and not yet treated. About 133 men will take the supplement or be observed. The goal is to see if the mushroom affects …

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This study tests a new approach for men with intermediate-risk prostate cancer. First, doctors use electric pulses (IRE) to destroy tumor cells, followed by precise radiation (MRgRT). The goal is to see if this combination is safe and can keep cancer away for at least a year. Abo…

This phase 3 trial tests whether adding darolutamide to standard hormone therapy (ADT) after prostate removal surgery can better prevent cancer from spreading in men with high-risk prostate cancer. The study enrolls 27 men who had their prostate removed and are at highest risk of…

This trial investigates whether real-time motion management techniques—like triggered imaging and MLC tracking—can safely reduce the target margins used during radiotherapy for prostate and lung cancer. By adjusting the radiation beam to follow tumor movement, researchers aim to …

This study tests whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink tumors in people with rare cancers of the urinary or reproductive systems. About 100 adults with advanced disease that cannot be removed by surgery are taking part. The main goal is t…

This trial tests whether placing a dehydrated human amnion chorion membrane (dHACM) over the nerves during robot-assisted prostate removal helps men recover erectile function and urinary control sooner. The study enrolls men aged 40 to 80 with localized prostate cancer who have g…

This phase 2 study tests a combination of radiation, hormone therapy (ADT), and two drugs (abiraterone and olaparib) in 21 men with prostate cancer that has spread to a few spots in the body. The goal is to see if this approach can prevent the cancer from growing or spreading fur…

This phase 3 trial tested enzalutamide (Xtandi) plus leuprolide in over 1,000 men with high-risk prostate cancer that had not spread but was progressing after initial treatment. The goal was to see if the combination could delay the cancer from spreading to other parts of the bod…

This phase 3 study tests whether adding darolutamide (Nubeqa) to standard hormone therapy (ADT) can delay cancer progression in men with high-risk biochemical recurrence of prostate cancer. About 985 men whose PSA levels rose after initial treatment will receive either darolutami…

This study tests a precise radiation technique called adaptive SBRT for men with high-risk or unfavorable intermediate-risk prostate cancer. The treatment targets the prostate and pelvic lymph nodes while giving an extra radiation boost to tumor spots seen on MRI. The goal is to …

This trial tests a minimally invasive treatment that uses microwaves to destroy only the cancerous part of the prostate, leaving healthy tissue intact. The goal is to control the cancer while avoiding common side effects of full prostate removal, such as urine leakage and erectil…

This study tests whether a device called Calypso, which tracks the prostate's position in real time during radiation, can reduce long-term side effects compared to standard image-guided radiation. 74 men with low- or intermediate-risk prostate cancer took part. The goal is to see…

This study tests a biodegradable balloon, called a rectal spacer, placed between the prostate and rectum before radiation therapy for prostate cancer. The goal is to see if it safely reduces radiation exposure to the rectum, potentially lowering side effects. Up to 150 men with l…

This study tests a device called Vanquish that uses water vapor (steam) to destroy prostate cancer tissue in men with intermediate-risk, localized prostate cancer. The goal is to control the cancer while avoiding common side effects like incontinence and impotence. About 400 men …

This phase 2 trial tests whether giving a combination of enteric-coated aspirin, rintatolimod, and interferon-alpha 2b before prostate cancer surgery can boost the immune system's attack on tumors. The study involves 12 men with localized prostate cancer who are scheduled for sur…

This phase II trial tests two types of radiation therapy (proton beam or IMRT) given in fewer, larger doses for men whose prostate cancer has returned or spread to a few spots after initial treatment. The main goal is to see if this shorter course causes fewer serious side effect…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This study tests whether adding the immunotherapy drug pembrolizumab can help men whose advanced prostate cancer has stopped responding to the standard drug enzalutamide. About 58 men with castration-resistant prostate cancer that has spread will receive pembrolizumab while conti…

This phase 3 trial tests whether adding enzalutamide to standard hormone therapy and radiation can delay cancer spread in 802 men with high-risk localized prostate cancer. Participants receive either enzalutamide or a conventional anti-androgen alongside hormone therapy and radia…

This study was designed for men with high-risk prostate cancer who are scheduled for prostate removal surgery. It planned to give a combination of three immunotherapy drugs (N-803, ETBX-071, and M-CENK) both before and after surgery to see if it could help prevent the cancer from…

This study compares a new, less invasive treatment called Aquablation, which uses a high-speed waterjet to remove prostate tissue, to standard surgery (radical prostatectomy) for men with localized prostate cancer. About 280 men will be randomly assigned to one of the two treatme…

This study tests whether adding darolutamide to standard hormone therapy and radiation can delay cancer spread in men with very high-risk localized prostate cancer. About 1,100 men are participating in this phase 3 trial. The goal is to see if the combination helps keep the cance…

This study compares two types of brachytherapy (radiation implants) for localized prostate cancer: low-dose-rate (seed) implants and high-dose-rate (temporary) implants. About 334 men will receive one of the two treatments. Researchers will measure how well each controls cancer a…

This pilot study tests two ultra-high-dose radiation schedules in 31 men with intermediate-risk prostate cancer. One group gets five high-dose sessions over a week; the other gets a single massive dose. The goal is to see if these shorter treatments are safe and can control the c…

This study tests whether giving a precise, high-dose radiation treatment (SBRT) before prostate removal surgery is safe and effective for men with high-risk prostate cancer. Sixteen men with aggressive prostate cancer (Gleason score 8 or higher or signs of spread) will receive ra…

This study tests whether a very short course of MRI-guided radiation (just 5 sessions) is safe and effective for men with low- or intermediate-risk prostate cancer. Traditional radiation can take 7-8 weeks, but this approach aims to cut that time dramatically. The trial involves …

This study looks at whether testosterone levels can return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will receive the drug combination and be monitored for testosterone recovery and …

This study tests whether using MRI guidance to deliver an extra dose of radiation directly to the tumor can improve prostate cancer treatment. Forty men with localized prostate cancer will receive standard radiation to the whole prostate plus a targeted boost to the visible tumor…

This phase 2 trial tests whether a shorter, more intense radiation course (SBRT) causes fewer side effects than standard daily radiation (IMRT) in men with high-risk prostate cancer. Both groups also receive hormone therapy. The study will compare side effects, quality of life, a…

This early-phase study tests whether a bicalutamide implant placed directly into the prostate can replace standard hormone shots for men with localized prostate cancer receiving radiation. About 20 participants with intermediate- or high-risk cancer will receive the implant plus …

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This phase II trial is testing whether combining antiandrogen drugs (leuprolide, apalutamide, abiraterone) with precise radiation (SBRT) can control prostate cancer that has come back and spread to a few other spots in the body. The study enrolls 28 men whose cancer has 1-5 visib…

This study tests a robotic system that uses a high-pressure water jet to remove prostate tissue in men with localized prostate cancer and trouble urinating. The goal is to see if the procedure is safe and works well. About 125 men will be followed for one year after treatment.

This trial is testing a new way to treat prostate cancer that returns after the prostate has been removed. It combines a very short course of highly targeted radiation (just 5 sessions) with 6 months of hormone therapy. The goal is to see if this approach can control the cancer w…

This study tests an experimental drug called [Ac-225]-PSMA-62 in people with prostate cancer that has spread to other parts of the body. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to find the safest dose and to see if it can shrink …

This study compares a newer hormone therapy (darolutamide) plus radiation against standard hormone therapy plus radiation for men with intermediate-risk prostate cancer. The goal is to see if the new approach controls the cancer just as well while helping men keep better erectile…

This early-phase trial tests an adaptive approach to hormone therapy for men with stage IV prostate cancer that still responds to hormone treatment. Instead of a fixed schedule, the treatment is adjusted based on PSA levels. The study includes 17 participants and combines standar…

This pilot study is testing whether robot-assisted prostate removal for localized prostate cancer can be safely performed as outpatient surgery, meaning patients go home the same day. Twenty men will be enrolled and followed for one month to see if they can avoid a conventional h…

This phase 2 trial tests whether taking omega-3 (EPA) supplements can reduce inflammation and slow cancer cell growth in men with high-risk prostate cancer who choose surgery. 130 participants will take either EPA capsules or a placebo for 14 months, starting before surgery. Rese…

This study tests a focused radiation technique called HDR brachytherapy for men whose prostate cancer has come back after earlier radiation treatment. The radiation is placed directly into the cancerous area and removed after a short time, aiming to spare healthy tissue. The tria…

This study tests a device that uses ultrasound energy guided by MRI to precisely destroy prostate cancer tumors while sparing healthy tissue. 62 men with localized prostate cancer will receive the treatment. The goal is to see if this approach is safe and effective at controlling…

This study was designed to test whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard hormone therapy and radiation could improve outcomes for men with high-risk localized prostate cancer. The trial was withdrawn before enrolling any participants, so no resul…

This phase II trial compares two types of radiation therapy for men with early-stage prostate cancer that hasn't spread. One method places a radioactive seed directly into the prostate for a few minutes, while the other delivers radiation from outside the body in five sessions. T…

This study follows 100 men with localized prostate cancer who received a condensed form of radiation called SBRT, which delivers high-dose radiation in just 5 treatments instead of the usual 42-45. Researchers are tracking how well the treatment controls cancer over time and how …

This phase 1 trial tests a combination of two radiation techniques for men with intermediate risk prostate cancer. First, a high dose of radiation is placed inside the prostate for 10-20 minutes (brachytherapy), followed by three weeks of highly targeted external radiation (SBRT)…

This study is testing whether a special type of MRI (multiparametric MRI) can better identify which men with low-risk prostate cancer can safely delay treatment. About 200 men already on active surveillance will receive the MRI, and if suspicious areas are found, they will get ad…

This study looks at whether a special type of MRI, called multiparametric MRI, can more accurately determine the stage of prostate cancer in people who are newly diagnosed and planning surgery. The goal is to see if this imaging method helps doctors find aggressive cancers and ma…

This phase 2 trial tests whether a radioactive tracer called 18F-DCFPyL can improve PET/CT scans for men with high-risk or recurrent prostate cancer. About 360 men will receive the tracer and undergo imaging to see if it more accurately finds cancer outside the prostate or after …

This study tests a new imaging agent called 68Ga-FAPI-46, which targets a protein (FAP) found around tumor cells. Researchers want to see where this tracer goes in the body and whether it can highlight prostate cancer on PET scans. About 30 people with prostate cancer who are alr…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study is testing a new way to detect prostate cancer by looking at cells in urine using a special imaging method. Researchers will collect urine samples from 675 men aged 50-75, including those with and without prostate cancer. The goal is to see if this simple test can accu…

This trial compares two biopsy methods for diagnosing prostate cancer in African American and white men with elevated PSA. One group gets a standard 12-core random biopsy, the other gets an MRI-guided fusion biopsy. The goal is to see which method more accurately detects clinical…

This study tests whether a new PET-CT scanner (RefleXion RMRS) can produce clear images of prostate cancer using a standard radioactive tracer. About 34 patients will receive both the standard scan and the new scan. If the new scanner works well, it may allow imaging and radiatio…

This study tests whether a special PET/CT scan (68Ga-PSMA-11) can help doctors plan more precise radiation for men whose prostate cancer has come back after surgery. About 193 men with a rising PSA level will be randomly assigned to have their radiation plan based on either the n…

This study tests whether a new device called OmnEcoil can safely and effectively combine two separate prostate cancer tests—MRI and biopsy—into a single procedure. About 45 men aged 45 and older with elevated PSA or abnormal exams will participate. The goal is to see if this appr…

This study tests a new 3D MRI technique to see if it can detect prostate cancer as well as or better than standard MRI, without needing an endorectal coil. It involves 33 men with untreated prostate cancer who are scheduled for surgery. The goal is to improve imaging comfort and …

This study tests whether a modified MRI scan (called Dixon sequencing) can produce clearer images of prostate cancer than the standard MRI. Researchers will compare the two methods in 65 men who have prostate cancer and are scheduled for prostate removal. The goal is to see if th…

This early-phase trial tests TRDC002, a radioactive tracer that attaches to PSMA proteins on prostate cancer cells, to improve PET/CT imaging in patients whose cancer has returned or spread. Six adults with PSMA-positive recurrent or metastatic prostate cancer will receive a sing…

This study tests whether a special whole-body MRI (diffusion-weighted imaging) can better detect prostate cancer that has spread to bones or lymph nodes compared to standard bone scans and CT scans. About 98 men with high-risk prostate cancer will undergo all three imaging method…

This study tests whether a special PET scan (68Ga-PSMA-11) can help guide prostate biopsies to find aggressive prostate cancer in men who had a previous negative or unclear biopsy. About 30 men with suspected cancer will receive the scan, and if it shows a suspicious spot, that a…

This study tests whether adding furosemide, a diuretic that increases urine flow, to a special PET/CT scan can reduce bladder radioactivity and improve detection of recurrent prostate cancer in 20 men whose PSA levels have risen after prostate removal. The goal is to see if this …

This study aimed to see if a special PET/MRI scan could better find aggressive prostate cancer in men with high PSA levels (2 ng/mL or more). The scan uses a radioactive tracer that attaches to cancer cells, making them show up on images. The trial was withdrawn before enrolling …

This phase III trial is testing whether a special ultrasound contrast agent, called Definity, can help doctors see prostate cancer on ultrasound images. The study involves 70 men scheduled for prostate removal surgery. Before surgery, they receive an IV of Definity, which contain…

This trial tests a biodegradable gel called SpaceOAR Vue that is injected between the prostate and rectum before radiation therapy. The gel temporarily pushes the rectum away to reduce radiation damage. About 500 men with intermediate-risk prostate cancer will be randomly assigne…

This early-stage study tests a high-precision radiation treatment called stereotactic body radiation therapy (SBRT) for men whose prostate cancer has returned after surgery. The main goal is to find the safest dose by monitoring side effects in 26 participants. The treatment deli…

This phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…

This pilot study tests a lifestyle intervention called Watchful Living for Black and Hispanic prostate cancer patients on active surveillance and their partners. The program includes nutrition counseling, an exercise plan, and telephone coaching to improve quality of life, physic…

This study tests a procedure called prostatic artery embolization (PAE) in 17 men with low-risk prostate cancer who also have trouble urinating. The goal is to see if PAE can reduce urinary symptoms before they start radiation therapy. Participants will have their symptoms and pr…

This study compares group telemedicine appointments to individual video visits for men with prostate cancer who are on active surveillance. Researchers want to see if the group format is practical and acceptable, and how it affects patient satisfaction and quality of life. The st…

This study tests whether using advanced MRI and daily CT scans during radiation therapy for low- to intermediate-risk prostate cancer can reduce side effects like bowel, bladder, and erectile problems. About 99 men will receive standard radiation but with more precise imaging to …

This phase 2 trial is testing whether a special type of radiation therapy (SAbR) that avoids the nerves involved in erections can help preserve sexual function in men with localized prostate cancer. About 124 men will be randomly assigned to receive standard SAbR or a version tha…

This study compares standard robotic prostate cancer surgery with or without an extra step called vesicopexy, which repositions the bladder to its normal place. The goal is to see if this addition helps men regain bladder control faster and improves their quality of life. About 1…

This study tests whether combining a stimulant drug (methylphenidate) with an exercise program can reduce severe fatigue in prostate cancer patients undergoing radiation and hormone therapy. About 200 participants will be assigned to drug plus exercise, drug alone, exercise alone…

This study tests a personalized rehabilitation program designed to help men recover their sexual quality of life after prostate removal for cancer. About 135 men will take part, with half receiving the program and half receiving standard care. The goal is to see if the program im…

This trial tests whether having an empty bladder before CT simulation for prostate cancer radiation therapy is better than the usual full bladder. The goal is to see if it reduces urinary symptoms and makes daily treatments more consistent. About 168 men with prostate cancer will…

This study looks at whether men with intermediate-risk prostate cancer can follow a Mediterranean diet before their surgery to remove the prostate. The goal is to see if this diet is practical and well-tolerated. Twelve participants will eat specially prepared meals and then unde…

This study looks back at the records of 625 men who had robotic prostate surgery for localized prostate cancer. It compares a newer single-port method with the standard multi-port approach to see which leads to fewer complications and better urinary control. The goal is to gather…

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This study follows 2,500 prostate cancer survivors who had surgery at City of Hope. Researchers track their quality of life, side effects, and long-term health for years after treatment. The goal is to learn what survivors experience over time and find ways to improve their care.

This study is testing whether a special type of MRI scan can show early signs that high-risk prostate cancer is responding to treatment. About 32 men will get the scan before and during therapy, and results will be compared to standard tissue exams after surgery. The goal is to f…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study follows 200 African American prostate cancer survivors and their partners to understand how daily stress, social support, and lifestyle choices like physical activity and diet affect each other. Participants wear an activity tracker and answer surveys on their smartpho…

This study looks at whether giving men with low-risk prostate cancer two extra tests—a genomic test (GPS) and a special MRI—helps them stick with active surveillance (monitoring instead of immediate treatment). Researchers will track 222 men for 18 months to see if these tests im…

This study looks at how the brain and pelvic floor muscles work together in men who have had or are having robot-assisted prostate surgery for prostate cancer. By recording brain activity (EEG) and muscle activity (EMG) during urination and Kegel exercises, researchers hope to id…

This study looked at whether regular screening tests for prostate, lung, colorectal, and ovarian cancers can help find cancer early and reduce deaths. Over 76,000 men and women took part, with some getting screened and others receiving usual care. The main goal was to see if scre…

This trial tests whether an artificial intelligence program can automate two key steps in radiotherapy planning: outlining areas at risk of tumor spread or radiation damage, and designing the radiation beams. The AI tool is compared against the standard manual process done by onc…

This study looks at inherited gene changes (like BRCA) in men with prostate cancer to understand how common they are and how they affect treatment. Researchers will collect saliva samples and health information from 1,360 men in Washington state. The goal is to improve cancer car…

This study explores whether a genetic test can identify prostate cancer patients at higher risk for urinary side effects from radiation therapy. Researchers will track side effects in 208 men with early-stage prostate cancer who receive stereotactic radiation. The goal is to see …

This study tests a new type of MRI that uses a special substance (hyperpolarized pyruvate) to see how active prostate cancer tumors are. Researchers want to know if this scan can find aggressive cancers and show if treatments are working or stopping sooner than standard scans. Ab…

This pilot study looks at whether special scans (PSMA PET/MRI) and genetic tests can predict how well high-risk prostate cancer responds to hormone therapy and radiation. Thirty participants will be followed for up to 5 years. The goal is to find markers that identify poor respon…

This study involves 400 men with high-risk prostate cancer who have not yet received treatment. Researchers are using a special type of scan called PSMA PET to see if it can find cancer that has spread to lymph nodes or other parts of the body, which standard scans often miss. Th…

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This pilot study tests a new MRI technique that uses a special form of bicarbonate to measure how acidic prostate tumors are. Ten men with localized prostate cancer will receive an injection of hyperpolarized bicarbonate before an MRI scan. The goal is to see if this method is sa…

This study looks at whether a special PET scan called Posluma can help doctors plan radiation therapy more precisely for prostate cancer. About 20 patients will get both a standard PET scan and an extra scan on the RefleXion X1 machine. The goal is to see if the new scan finds th…

This study is looking at tiny particles called extracellular vesicles that come from prostate cancer cells. Researchers want to see if levels of these particles in blood and urine can show how well surgery removed the cancer. They will compare samples from prostate cancer patient…

This study tests a lifestyle program for African American men who have finished prostate cancer treatment and their spouses or partners. The goal is to see if the program can improve quality of life, diet, physical activity, and partner support. Only 6 participants were enrolled,…

This study looks at how hormone therapy (anti-androgen treatment) for prostate cancer affects the heart. Researchers will use heart MRI scans before and after 4-7 months of treatment in 23 men. The goal is to understand changes in heart function, not to treat the cancer itself.

This study aimed to collect prostate tissue samples from men undergoing brachytherapy for prostate cancer. The goal was to build a biobank for research into how the cancer responds to radiation. No participants were enrolled, and the study was withdrawn before it began.

This study looks at how certain hormone therapies for advanced prostate cancer might affect memory, thinking, and brain structure. Researchers will use brain scans and thinking tests in 100 men to track changes over time. The goal is to understand which patients are more likely t…

This study looks at how certain hormone therapies for prostate cancer affect the heart. It compares two drugs, leuprolide and relugolix, given alongside radiation. The goal is to understand why some men develop heart problems and find ways to predict and reduce that risk. About 9…

This study looks at new ways to predict how prostate cancer and nearby healthy tissues react to a precise type of radiation therapy called SBRT. Researchers will analyze breath samples, blood DNA, and CT scans from 60 men with low- or intermediate-risk prostate cancer. The goal i…

This study interviews 80 immigrant men from Sub-Saharan Africa and the Caribbean who have been diagnosed with prostate cancer. Researchers want to understand how social factors like where they come from affect their health decisions, treatment, and survival. The goal is to identi…

This study looks at whether removing lymph nodes during prostate cancer surgery helps prevent the cancer from coming back in men with intermediate-risk prostate cancer. Currently, the procedure is standard but can cause side effects like swelling, blood clots, or nerve injury. Th…

This study aims to see how prostate tumors change on MRI scans shortly after a precise type of radiation therapy (SBRT). Researchers will compare these MRI changes with PSA levels in the blood. The study involves 28 men with localized prostate cancer and is designed to improve un…

This study explores whether special PET scans (PSMA-PET) can better track how well treatment is working in men with metastatic hormone-sensitive prostate cancer. Twenty participants will receive standard care and undergo scans before and after 6 months of treatment. The goal is t…